Guiding Cells to Improve Life
Fate Therapeutics is a clinical‑stage biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe, life‑threatening diseases. We have built a novel platform to program the function and fate of cells ex vivo using pharmacologic modulators, such as small molecules. We are focused primarily on developing programmed hematopoietic cellular candidates as therapeutic entities for the treatment of hematologic malignancies, rare genetic disorders, and diseases resulting from the dysregulation of the immune system.
Our lead product candidate, ProHema, is an ex vivo programmed hematopoietic cellular therapeutic which is currently in clinical development for the treatment of hematologic malignancies and rare genetic disorders in patients undergoing hematopoietic stem cell transplantation (HSCT). ProHema is produced by programming the biological properties of hematopoietic stem cells (HSCs) and T cells of umbilical cord blood ex vivo using the small molecule modulator, FT1050 (dmPGE2). This modulation process induces rapid activation of genes involved in the homing, proliferation and survival of HSCs and in the cell cycle, reactivity and anti‑viral properties of T cells. In addition to ProHema we are developing an ex vivo programmed mobilized peripheral blood product for use in allogeneic HSCT, and plan to submit an IND to the FDA for this product in 2015.
Behind these development-stage programs, we have active research programs aimed at broadening our a pipeline to programmed HSCs and programmed T cells as therapeutic entities for use beyond the HSCT setting. We have built a leadership position in the identification of pharmacologic modulators, including combinations of modulators, that promote rapid and supra‑physiologic activation or inhibition of therapeutically‑relevant genes and cell‑surface proteins on HSCs and T cells. By example, our most advanced research-stage program is an ex vivo programmed HSC cell that is modulated by a triple modulator combination that programs human HSCs to express high levels of PD-L1, a key immunosuppressive protein.
In addition to the use of small molecules to program cell function, we have developed proprietary, small-molecule enhanced induced pluripotent stem cell (iPSC) technology that allows us to program cell fate. Differentiation of iPSCs to therapeutic cells in the hematopoietic lineage, such as HSCs, T cells, and natural killer (NK) cells, holds promise as a potentially disruptive approach for developing next generation cellular therapeutics, including genetically engineered hematopoietic cellular therapeutics.